Recap: Adaptimmune Therapeutics Q1 Earnings

Shares of Adaptimmune Therapeutics ADAP rose 1.3% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were flat 0.00% year over year to ($0.04), which beat the estimate of ($0.25).

Revenue of $761,000 rose by 0.00% from the same period last year, which missed the estimate of $23,290,000.

Outlook

Adaptimmune Therapeutics hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: May 14, 2020

Time: 08:02 PM ET

Webcast URL: https://edge.media-server.com/mmc/p/4772jrtc

Technicals

52-week high: $6.00

52-week low: $0.71

Price action over last quarter: Up 27.07%

Company Description

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNews
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!